Join OBIO on Tuesday, June 26th to identify non-dilutive funding programs, learn to prepare your applications, and what you should be aware of after being awarded. Sign up for one or all of four sessions designed to help you build your early-stage strategy toolbox.
On June 25th, join OBIO for a unique opportunity to hear from experienced investors and analysts about how VCs think about valuation and how valuation is translated into deal structure.
Find out more about:
ROI needed for investors
Valuation methods commonly used
Criteria for selecting comparable companies
Characteristics of equity and debenture instruments
Consequences of dilution and follow-on investment
Calculating exit payouts
Red flags and how to prepare to discuss valuation with investors
Get behind-the-scenes on the recent changes at the FDA and learn more about how regulatory process changes affect your company:
Understand FDA’s vision and approach to driving innovation under Commissioner Dr. Scott Gottlieb, and how recent changes in the agency will affect premarket submissions and inspections.
Learn how and when you should be engaging with the FDA.
Find out what the FDA is looking for in 510(k), DeNovo, and PMA submissions & recent approvals of devices with AI and machine learning features.
Join OBIO on Tuesday, June 12th to hear from industry experts on the importance of strategic marketing for health science companies, featuring our keynote speaker, Dr. Brian Jahns, the Senior VP, Commercial and Business Development at Trillium Therapeutics Inc. where he is responsible for providing commercial input clinical and regulatory strategy, as well as carrying out business development activities. Dr. Jahns will discuss why it’s critical for early stage health science companies to develop a strategic plan, the impact of those plans on successful commercialization and lessons learned from his experience in the health science industry.
If you are heading to RESI or BIO in Boston, please join Gail Garland, OBIO CEO, for dinner and an opportunity to network and exchange notes with fellow OBIO companies. Adam Buckley, VP of Business Development, VBI Vaccines and OBIO Board Director, will speak about the VBI Vaccines story.
On May 3, OBIO welcomed health science leaders, CEOs and the investment community to the tenth annual OBIO Leadership Event. Hosted at SPiN, the event also saw the launch of Use It or Lose It: Industry Solutions to Ontario's Commercialization Gap, OBIO's 2018 Industry Report. Check out the event photo gallery and recap.
Get an in-depth view of the attractive non-dilutive funding programs offered by CQDM which have supported several Ontario health science companies.
✓ Quantum Leap & SynergicQc Programs
✓ Application & Funding Process
✓ Mentorship & Large Pharma Partners
OBIO will be hosting Pfizer Global at ONRamp (100 College Street, Suite 158) for a workshop and partnering day. Representatives from Pfizer Global will be present to discuss Pfizer’s partnering philosophy, as well as the interests of individual research units. They will also discuss Pfizer’s unique approach to drug discovery. Following the workshop and Q&A session, there is also the opportunity to meet one-on-one with a Pfizer representative to discuss potential partnering opportunities. If interested, please register by March 14th, and request a one-on-one as part of the registration process.
OBIO is partnering with NRC-IRAP’s Biomedical Sector Team on a workshop on how Canadian companies and researchers can access funding, directly or indirectly, from the US National Institutes of Health (NIH).
This interactive workshop will help with business plan development through key learnings such as:
Gathering and using decision making analytics
Business plan components and prioritization
Raising capital for early stage health science companies
Join OBIO® on Tuesday, February 6th for a seminar delivered by Professional Coaches and Digital/Strategic Marketing experts.
Joel Ironstone is a medical technology development expert with over 15 years of consulting experience developing novel medical technologies. His experience includes technical development, regulatory approvals and the design and execution of clinical trials.
Presented by Bausch + Lomb
Bausch + Lomb is a subsidiary division of the multinational specialty pharmaceutical company, Valeant Pharmaceuticals International, located in Quebec, Canada. B+L operates within the health care and optics space, with a major focus on marketing, sales and distribution of vision care products.
Looking for the latest funding programs or a valuable partnership? Go beyond combing websites and come to OBIO's “Meet the Non-Dilutive Money!”
Representatives will be Live & In Person from:
- Ontario Centres of Excellence (OCE)
- Ontario Genomics Institute (OGI)
OBIO’s ½ day workshop on health economics, in partnership with and hosted by St. Michael’s Hospital Toronto, will include the following topics:
- The role of payors in healthcare technology adoption in major jurisdictions
- Understanding, designing and executing trials to show product value
- Pricing and market access strategies driven by Health Economics
OBIO® invites you to a unique opportunity to hear Andrew Hutchinson of Alexion Pharmaceuticals, a global pharmaceutical company, provide his valuable insights on best practices for approaching strategic partners in the pharmaceutical industry. Andrew is an External Research & Scouting Lead and is focused on the search, identification and evaluation of business development opportunities for Alexion Pharmaceuticals.
Presented by Kevin Fernandes, M. Eng, P.ENG
CEO, SRED SOLUTIONS
How Big is Your Market Really? Market Segmentation
Presented by Nick Kuryluk of Virtus Insights
Bruce Clarke of B2 Consulting Group will educate participants on:
- Leveraging Market Research
- Case Examples: Validating Value Proposition/Business + Concept/Product
- How to Get Data When You Don’t Have Much Money
- What You Need/Can Do at Each Stage (Ideation, Product Development / Pre-Clinical, Product Launch, Commercial)
OBIO® invites you for the unique opportunity to hear Grant Blevins of FCA Venture Partners, an early stage US venture capital firm, provide his valuable insights on raising capital in the digital health industry via webinar.
OBIO’s H2BB workshop on Market Segmentation will address how to identify different groups of customers and how to use this information to drive your strategy
This workshop will provide an overview of the process illustrated with several relevant examples
OBIO’s H2BB workshop on Primary Market Research will help you understand what primary market research is , what questions it can answer and how it can help you.